KLOR-CON- potassium chloride powder, for solution
Upsher-Smith Laboratories, LLC
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use KLOR-CON® safely and effectively. See full prescribing information for KLOR-CON®.
KLOR-CON® Powder (potassium chloride) for oral solution
Initial U.S. Approval: 1948
INDICATIONS AND USAGE
Potassium chloride is a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. (1)
DOSAGE AND ADMINISTRATION
If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral supplementation. (2.1)
Treatment of hypokalemia:
Maintenance or Prophylaxis of hypokalemia:
DOSAGE FORMS AND STRENGTHS
WARNINGS AND PRECAUTIONS
Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Upsher-Smith Laboratories, LLC at 1-855-899-9180 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Cirrhosis: Initiate therapy at the low end of the dosing range. (8.6)
Renal Impairment: Initiate therapy at the low end of the dosing range. (8.7)
FULL PRESCRIBING INFORMATION: CONTENTS*
Klor-Con® powder (potassium chloride) is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral supplementation.
Monitor serum potassium and adjust dosages accordingly. For treatment of hypokalemia, monitor potassium levels daily or more often depending on the severity of hypokalemia until they return to normal. Monitor potassium levels monthly to biannually for maintenance or prophylaxis.
The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms and the clinical status of the patient. Correct volume status, acid-base balance and electrolyte deficits as appropriate.
Dilute the potassium chloride for oral solution with 4 ounces of cold water or other beverage [see Warnings and Precautions (5.1)].
Take with meals or immediately after eating.
Treatment of hypokalemia:
Daily dose range from 40 to 100 mEq. Give in 2 to 5 divided doses: limit doses to 40 mEq per dose. The total daily dose should not exceed 200 mEq in a 24 hour period.
Maintenance or Prophylaxis:
Typical dose is 20 mEq per day. Individualize dose based upon serum potassium levels.
Studies support the use of potassium replacement in digitalis toxicity. When alkalosis is present, normokalemia and hyperkalemia may obscure a total potassium deficit. The advisability of use of potassium replacement in the setting of hyperkalemia is uncertain.
Treatment of hypokalemia:
Pediatric patients aged birth to 16 years old: The initial dose is 2 to 4 mEq/kg/day in divided doses; do not exceed as a single dose 1 mEq/kg or 40 mEq, whichever is lower; maximum daily doses should not exceed 100 mEq. If deficits are severe or ongoing losses are great, consider intravenous therapy.
Each packet contains 1.5 g of potassium chloride supplying 20 mEq of potassium and 20 mEq of chloride.
May cause gastrointestinal irritation. Increased dilution of the solution and taking with meals may reduce gastrointestinal irritation [see Dosage and Administration (2.1)].
The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.
Use with potassium-sparing diuretic can produce severe hyperkalemia. Avoid concomitant use.
Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.
The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.
Clinical trial data from published literature have demonstrated the safety and effectiveness of potassium chloride in children with diarrhea and malnutrition from birth to 16 years.
Clinical studies of potassium chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently [see Clinical Pharmacology (12.3)].
Patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. Patients with impaired renal function, particularly if the patient is on ACE inhibitors, ARBs, or nonsteroidal anti-inflammatory drugs should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia. The serum potassium level should be monitored frequently. Renal function should be assessed periodically.
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly potentially fatal hyperkalemia can result.
Hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).
Treatment measures for hyperkalemia include the following:
In patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.
Potassium chloride is a white crystalline or colorless solid. It is soluble in water and slightly soluble in alcohol. Chemically, potassium chloride is KCl with a molecular mass of 74.55.
Each packet of light orange powder contains 1.5 g potassium chloride, USP, which is equivalent to potassium 20 mEq and chloride 20 mEq. Each packet of Klor-Con powder contains the following inactive ingredients: FD&C Yellow No. 6, malic acid, neotame, and natural orange flavor (Modified food starch (with added corn syrup), maltodextrin, citric acid, silicon dioxide and natural tocopherols).
The potassium ion (K+) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function.
The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.
Potassium is a normal dietary constituent, and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.
Based on published literature, the rate of absorption and urinary excretion of potassium from KCl oral solution were higher during the first few hours after dosing relative to modified release KCl products. The bioavailability of potassium, as measured by the cumulative urinary excretion of K+ over a 24 hour post dose period, is similar for KCl solution and modified release products.
Klor-Con® powder (potassium chloride for oral solution, USP) is a light orange powder available in one strength as follows:
Each packet contains 1.5 g of potassium chloride providing potassium 20 mEq and chloride 20 mEq supplied in:
|Cartons of 30 packets||NDC 0245-0360-30|
|Cartons of 100 packets||NDC 0245-0360-01|
UPSHER-SMITH LABORATORIES, LLC
Maple Grove, MN 55369
Klor-Con is a registered trademark of Upsher-Smith Laboratories, LLC.
potassium chloride powder, for solution
|Labeler - Upsher-Smith Laboratories, LLC (047251004)|
|Upsher-Smith Laboratories, LLC||079111820||MANUFACTURE(0245-0360) , LABEL(0245-0360) , PACK(0245-0360)|
|Upsher-Smith Laboratories, LLC||047251004||ANALYSIS(0245-0360)|